Back to search

France· FR:66610933

XELJANZ 11 mg, comprimé à libération prolongée

A medicinal product containing citrate de tofacitinib, registered in France by PFIZER EUROPE MA EEIG (BELGIQUE), on the national reimbursement list.

Reimbursed in France (Assurance maladie)

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedXELJANZ 11 mg, comprimé à libération …ATC—REGISTER NO.FR:66610933PACKS LISTED1CHECKEDSeptember 12, 2026

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
CITRATE DE TOFACITINIB
Manufacturer
PFIZER EUROPE MA EEIG (BELGIQUE)
Country
France (FR)
ATC code
—
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400930199893
    plaquette(s) aluminium PVC-Aluminium de 28 comprimés
    EUR 634.25

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Citrate de tofacitinib in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All citrate de tofacitinib products

Authorised across Europe · EMA

The same active substance is authorised in 14 EEA countries. Names it is sold under:

  • Austria · Tofacitinib Devatis, Tofacitinib Stada
  • Bulgaria · Tофацитиниб Devatis
  • Denmark · Tofacitinib Accord, Tofacitinib Newbury
  • Spain · Tofacitinib Stada
  • Finland · Tofacitinib Devatis, Tofacitinib Stada
  • United Kingdom (Northern Ireland) · Tofacitinib Amarox, Tofacitinib Brown & Burk Uk
  • Croatia · Tofacitinib Accord, Tofacitinib Stada
  • Iceland · Xeljanz
  • Liechtenstein · Xeljanz
  • Malta · Tofacitinib Stada
  • Netherlands · Tofacitinib Devatis, Tofacitinib Stada
  • Norway · Tofacitinib Accord, Tofacitinib Devatis
  • Portugal · Tofacitinib Bluepharma
  • Sweden · Tofacitinib Devatis, Tofacitinib Newbury

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ff5ae20d-f58b-4480-a27f-768cd9989f98
GET /v1/drugs/ff5ae20d-f58b-4480-a27f-768cd9989f98?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "66610933",
  "date_amm": "2019-12-16",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/17/1178",
  "substance": "CITRATE DE TOFACITINIB",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "comprimé à libération prolongée",
  "voies_administration": "orale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about citrate de tofacitinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.